VRTX250110C280000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Vertex Grapples With Bearish Chart As Death Cross Emerges
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
Vertex, Orna Therapeutics Collaborate on Gene Editing Therapies for Sickle Cell Disease, Beta Thalassemia
RBC Lifts Price Target on Vertex Pharmaceuticals to $401 From $400, Keeps Sector Perform Rating
Orna Therapeutics Enters Three-year Strategic Research Collaboration With Vertex Pharmaceuticals; Orna To Receive $65M Upfront Payment And Is Eligible To Receive Up To $635M Milestones
Express News | Vertex Pharmaceuticals Inc - Orna to Receive $65 Million Upfront, Eligible for up to $635 Million
Express News | Orna Therapeutics Establishes Strategic Collaboration With Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (Scd) and Transfusion-Dependent Beta Thalassemia (Tdt)
Orna Therapeutics Establishes Strategic Collaboration With Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $441
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
Revenues Not Telling The Story For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
Those Who Invested in Vertex Pharmaceuticals (NASDAQ:VRTX) Three Years Ago Are up 79%
Is the Options Market Predicting a Spike in Vertex Pharmaceuticals (VRTX) Stock?
10 Health Care Stocks With Whale Alerts In Today's Session
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Express News | JPMorgan: Downgraded the Target Price of Vertex Pharmaceuticals from $503 to $500, but maintained the Shareholding rating.
Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): 'This Is Hardly Down For The Year. I Think It Can Still Go Lower'
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $460